EU clears Roche’s Polivy for certain lymphomas
admin 21st January 2020 Uncategorised 0The drug has been approved in combination with bendamustine and MabThera. More: EU clears Roche’s Polivy for certain lymphomas Source: News
read more
The drug has been approved in combination with bendamustine and MabThera. More: EU clears Roche’s Polivy for certain lymphomas Source: News
read moreBreast cancer is the most common type of cancer in the UK, with around 55,000 new cases each year. More: New scan could see active breast tumour regions in ‘real-time’ Source: News
read moreNovartis also expects NICE and SMC decisions in the first half of 2020. More: EMA licenses Mayzent for MS Source: News
read moreOf the 60 products in development, very few seem to show benefit over existing treatments. More: ‘Weak antibiotic pipeline’ poses threat to AMR fight Source: News
read moreThe UK is “well on its way towards our ambition of zero HIV transmissions by 2030.” More: HIV transmissions fall by 71% Source: News
read moreDue to the aging global population, recent years have seen an increased prevalence of chronic HF. More: Heart failure market could surpass ‘bn by 2028’ Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals